| 引用本文：崔鹏磊, 李世勇, 常峰, 路云.药品风险分担协议对中国大陆的启示——以澳大利亚、新西兰、中国台湾为例[J].中国卫生政策研究,2017,10(2):21-26 |
|
| 药品风险分担协议对中国大陆的启示——以澳大利亚、新西兰、中国台湾为例 |
| 投稿时间：2016-08-29 修订日期：2016-11-06 PDF全文浏览 HTML全文浏览 |
| 崔鹏磊1, 李世勇2, 常峰1, 路云1 |
1. 中国药科大学国际医药商学院 江苏南京 211198;
2. 深圳职业技术学院 广东深圳 518055 |
| 摘要:在新医疗技术不断推陈出新，药品疗效和效果存在不确定性，患者健康期望值增加以及政府和保险机构面临财政预算压力的背景下，风险分担协议逐渐成为许多国家政府或保险机构关注的焦点。本文将从主管机构、适用范围、类型划分、应用流程、实施效果5个方面分析澳大利亚、新西兰和中国台湾的药品风险分担协议政策，提出我国应完善药品风险分担协议理论基础、多样化风险分担协议类型、标准化风险分担协议流程等内容，以进一步完善我国药物政策。 |
| 关键词:药品风险分担协议 不确定性 成本效果 |
|
| The implementing experience of pharmaceutical risk-sharing agreements in Australia, New Zealand, Taiwan area and its implication for mainland China |
| CUI Peng-lei1, LI Shi-yong2, CHANG Feng1, LU Yun1 |
1. School of International Pharmaceutical Business China Pharmaceutical University, Nanjing Jingsu 211198, China;
2. Shenzhen Polytechnic, Shenzhen Guangdong 518055, China |
| Abstract:With the rapid development of healthcare technologies, the improvement of patient health expectations, and the increasing of the government or insurer's financial budget pressure, risk-sharing agreements has become the focus of the governments or insurer concerned. This article systematically analyzed Australia, New Zealand, Taiwan risk-sharing agreements from five aspects, including the operation main, scope, classification, application processes and the implementation effects. According to the results of the analysis, we suggests that China should improve risk-sharing agreements theoretical basis, diversify risk-sharing agreements models, establish risk-sharing agreements standardization process and so on. |
| Key words:Risk-sharing agreements Uncertainly Cost-effectiveness |
| 摘要点击次数: 2043 全文下载次数: 22 |
|
|
|
|
|
